STAT+: Narcan manufacturer aims to price over-the-counter kit under $50
The manufacturer of Narcan, the overdose reversal medication that received over-the-counter status last month, says…
Category: STAT+
STAT+: Powerful Senate duo drops a bipartisan PBM reform plan
WASHINGTON — The chair and ranking Republican on the Senate Finance Committee on Thursday unveiled…
STAT+: Pharmalittle: White House to tap cancer center chief to lead NIH; generic abortion pill maker sues FDA
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: The high hopes — and high stakes — behind Microsoft and Epic’s plan to use AI to answer patient questions
Generative artificial intelligence tools have triggered a flood of speculation about the technology’s ability to…
STAT+: Stock drama, cancer vaccine success, and new science – highlights from AACR
ORLANDO, Fla. – There was some drama at the American Association for Cancer Research annual…
.jpg)
STAT+: Congress targets reducing hospital outpatient payments in new bills
WASHINGTON — House Republicans are floating several draft bills that would significantly affect the hospital…
STAT+: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs
WASHINGTON — Senators grilled FDA Commissioner Rob Califf Wednesday on everything from the agency’s stance…
STAT+: Senate still hasn’t made hard decisions on lowering insulin costs
WASHINGTON — Senate Democrats are trying to cap insulin costs for every American, but they…
STAT+: PhRMA execs paint grim picture of industry under Medicare drug price negotiation
WASHINGTON — Executives for the brand drug industry’s biggest lobbying group painted a grim picture…
STAT+: Amazon strikes partnership with 3M to advance conversational AI in medicine
Health care companies are joining forces with big tech players as they race to integrate…
STAT+: STAT-Harris Poll: Most Americans are worried about RSV
A majority of Americans are concerned about the health threat posed by the respiratory syncytial…
STAT+: Pharmalittle: GSK manufacturing workers in the U.K. to strike in May; weight-loss drugs prompt strange dreams
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Relay’s breast cancer drug proves tolerable, but market is unimpressed
ORLANDO, Fla. — Researchers presented early phase trial results on RLY-2608, Relay Therapeutics’ next-generation PI3K…
STAT+: Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma
The CAR-T cancer therapy called Carvykti, made by Johnson & Johnson and Legend Biotech, reduced…
STAT+: Mindpath seemed like a success story for private equity in mental health. Now, it’s a cautionary tale
As a Covid-driven mental health crisis enveloped the U.S. in 2020, two private equity firms…
STAT+: Mark Cuban’s drug company creates a pharmacy network to challenge PBMs
In its latest bid to upend the pharmaceutical supply chain, the Mark Cuban Cost Plus…
STAT+: Novel strategy of attacking sugars on cancer cells to free immune system shows promise in early tests
ORLANDO, Fla. — Many cancer cells shroud themselves in a thicket of complex sugars called…
STAT+: Pharmalittle: GSK will buy Bellus Health for $2 billion; FDA inspectors are leaving faster than they can be replaced
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Define Ventures raises $460 million to fuel early-stage health tech startups
At a challenging time for digital health startups, Define Ventures announced on Tuesday it has…
.jpg)
STAT+: Most large U.S. funders of clinical research have poor transparency policies, analysis finds
Amid ongoing concern over clinical trial transparency, a new analysis finds that only 37% of…
STAT+: Why do some blood stem cells go rogue? Study offers clue and possible target
ORLANDO, Fla. – Long before leukemia forms, patients often have a population of blood or…
STAT+: Pharmalittle: Merck to acquire Prometheus Biosciences for $10.8 billion; mRNA cancer vaccine reduces melanoma relapse
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A bellwether moment: Once a distant dream, gene therapy for Duchenne nears historic decision
Brent and Sabina Furbee could see something was wrong with their son, Emerson, even if…
STAT+: Moderna’s mRNA cancer vaccine shows promise in combination with melanoma drug
ORLANDO, Fla. — For years, early experimental results offered hope that scientists might be able…
STAT+: UnitedHealth says medical costs aren’t soaring. The reality is murkier
Executives at UnitedHealth Group hinted Friday that hospitalizations are not rising and that people are…
STAT+: Pharmalittle: Telehealth abortion providers are scrambling; Express Scripts launches new pricing plan amid PBM scrutiny
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ‘Style over substance?’ Express Scripts launches new pricing plan amid rising scrutiny of PBMs
Amid increasing scrutiny of pharmacy benefit managers, Express Scripts is launching a new pricing plan…
STAT+: Congress is launching a tobacco harm reduction caucus. Its biggest supporter so far? Philip Morris
WASHINGTON — There’s a new caucus brewing on Capitol Hill focused on the potential health…
STAT+: Medicare advisers endorse reforms to lower drug spending
In the latest move to address prescription drug pricing, the Medicare Payment Advisory Commission unanimously…
STAT+: Flawed AI algorithms can cause harm in medicine. A research team has a plan to root out bias and improve accuracy
There are a lot of ways that artificial intelligence can go awry in health and…
STAT+: Federal group studying surprise ambulance bills will finally meet — five months late
The federal committee in charge of finding ways to stop surprise billing from ground ambulances…
STAT+: Pharmalittle: Appeals court allows access to abortion pill, but with restrictions; FDA official intervened on behalf of Sarepta gene therapy
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Google will let health care customers test its generative AI model, ramping up rivalry with GPT-4
Accelerating medicine’s AI race, Google is releasing a version of its generative language model to…
STAT+: Pear Therapeutics dreamt of huge revenues and ‘commercial scale.’ It never came close
In January, Pear Therapeutics was quickly running out of money. The digital health startup embarked…
STAT+: FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened
Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene…
STAT+: Sickle cell gene therapies could be cost-effective even if priced as high as $1.9 million
As the U.S. health care system prepares for expensive gene therapies, a preliminary analysis suggests…
STAT+: Senate hashing out policy details on generics, PBMs, insulin
WASHINGTON — Senators are slightly delaying their latest legislative push on health care, but as they…
STAT+: Sanders plans to haul insulin executives to testify in Senate
WASHINGTON — Sen. Bernie Sanders plans to call the chief executives of the country’s largest…
STAT+: Pharmalittle: Where is PhRMA in the abortion pill debate? Most late-stage MS drug trials were never published
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Just how big of a pay bump do hospitals need from Medicare next year?
The federal government is proposing to give hospitals a 2.8% raise in their Medicare payments…
STAT+: How many? One-third of late-stage trials testing multiple sclerosis drugs were never published
The results from more than one-third of late-stage clinical trials that tested multiple sclerosis drugs…
STAT+: Oracle’s Cerner Enviza launches a new effort to use AI to study asthma drug safety
Cerner Enviza is partnering with health care AI company John Snow Labs to develop artificial…
STAT+: Pharmalittle: Pharma execs call for reversal of abortion pill ruling; U.S. to spend $5 billion to speed Covid-19 treatments
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: A biotech upstart takes on cancer by crowdsourcing the immune system’s natural killers
No two people have quite the same immune system. And while that fact can make…
STAT+: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation
Amid an investigation of alleged research misconduct, Stanford University’s president took responsibility in an email…
STAT+: Pharmalittle: Abortion pill ruling could threaten FDA approval authority; Lilly CEO warns EU pharma legislation will hurt innovation
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: 5 tech startups trying to solve health care’s staffing crisis to watch
Three years after the pandemic upended the health care workforce, hospital staffing is still a…
STAT+: Pharmalittle: Genentech finds no evidence of fraud in paper by former top exec; FDA withdraws approval for premature-birth drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Liver disease researchers are hoping AI can improve their trial design
Liver disease researchers, stumped by a complex disease, are looking for new investigative tools. Artificial…
STAT+: Wall Street embraces health insurers after scoring Medicare Advantage payment win
Health insurance companies that participate in Medicare Advantage will retain billions of extra taxpayer dollars…